FDA-Approved Label Change for Cimzia Important for Childbearing Women with Inflammatory Diseases
The U.S. Food and Drug Administration approved a label update stating there is negligible to low transfer of UCB’s Cimzia (certolizumab pegol) through the placenta and minimal transfer in breast milk from mother to infant. This information will assist healthcare providers in providing care to women with chronic inflammatory…